These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22451467)

  • 1. [Preclinical and clinical data of the synthetic Xa inhibitor fondaparinux (Arixtra(®))].
    Suzuki I; Ozeki Y
    Nihon Yakurigaku Zasshi; 2012 Mar; 139(3):117-26. PubMed ID: 22451467
    [No Abstract]   [Full Text] [Related]  

  • 2. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy.
    Turpie AG
    Expert Opin Pharmacother; 2004 Jun; 5(6):1373-84. PubMed ID: 15163281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
    Kabuki T; Nakanishi R; Hisatake S; Fujii T; Dobashi S; Wakakura S; Kiuchi S; Fujino T; Ikeda T
    J Cardiol; 2017 Aug; 70(2):163-168. PubMed ID: 27979674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidetector-row computed tomography-based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients.
    Nakamura M; Okano Y; Minamiguchi H; Munemasa M; Sonoda M; Yamada N; Hanzawa K; Aoyagi N; Tsujimoto H; Sarai N; Nakajima H; Kunieda T
    Circ J; 2011; 75(6):1424-32. PubMed ID: 21512258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New anticoagulants -- their clinical significance].
    Haas S
    Ther Umsch; 2003 Jan; 60(1):19-23. PubMed ID: 12638473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fondaparinux (Arixtra), a new anticoagulant.
    Med Lett Drugs Ther; 2002 May; 44(1130):43-4. PubMed ID: 12011755
    [No Abstract]   [Full Text] [Related]  

  • 7. Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism.
    Robinson DM; Wellington K
    Am J Cardiovasc Drugs; 2005; 5(5):335-46. PubMed ID: 16156690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent.
    Walenga JM; Jeske WP; Samama MM; Frapaise FX; Bick RL; Fareed J
    Expert Opin Investig Drugs; 2002 Mar; 11(3):397-407. PubMed ID: 11866668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of fondaparinux for the prevention and treatment of venous thromboembolism.
    Turpie AG
    Expert Opin Drug Saf; 2005 Jul; 4(4):707-21. PubMed ID: 16011449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
    Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E
    Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arixtra (fondaparinux sodium).
    Mousa SA
    Methods Mol Med; 2004; 93():239-46. PubMed ID: 14733336
    [No Abstract]   [Full Text] [Related]  

  • 12. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Kearon C; Kahn SR; Agnelli G; Goldhaber S; Raskob GE; Comerota AJ
    Chest; 2008 Jun; 133(6 Suppl):454S-545S. PubMed ID: 18574272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).
    Samama MM; Gerotziafas GT
    Thromb Res; 2003 Jan; 109(1):1-11. PubMed ID: 12679126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fondaparinux sodium: a selective inhibitor of factor Xa.
    Bauer KA
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 2():S14-7. PubMed ID: 11715834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
    Blick SK; Orman JS; Wagstaff AJ; Scott LJ
    Am J Cardiovasc Drugs; 2008; 8(2):113-25. PubMed ID: 18422394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Update on current care guidelines: venous thrombosis and pulmonary embolism].
    Duodecim; 2010; 126(13):1607-8. PubMed ID: 20695303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentasaccharides.
    Turpie AG
    Semin Hematol; 2002 Jul; 39(3):158-71. PubMed ID: 12124678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
    Morishima Y; Kamisato C; Honda Y
    Eur J Pharmacol; 2014 Nov; 742():15-21. PubMed ID: 25179572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor X inhibitors.
    Tan KT; Makin A; Lip GY
    Expert Opin Investig Drugs; 2003 May; 12(5):799-804. PubMed ID: 12720491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Conventional or low molecular weight heparin in the treatment of venous thromboembolic disease?].
    Ruiz Manzano J; Monreal M
    Med Clin (Barc); 1998 Nov; 111(18):697-9. PubMed ID: 9887434
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.